Despite universal access to HER2 testing in Ontario, variability in reporting by region and disease severity presents challenges for program evaluation and quality improvement initiatives.
Ilia L. Ferrusi, PhD
Advertisement
Articles by Ilia L. Ferrusi, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
2
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
3
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
4
Childhood Influenza Vaccine Rates Decreased From 2017 to 2023
5